Abstract: Methods and systems are disclosed for sandbox based internet isolation system in a trusted network. A networked computer system may include a trusted local area network (LAN) and at least one host computer system connected to the trusted LAN. The host computer system may include a host-based firewall, an operating system, a first memory space, and a second memory space. The host-based firewall may be configured to prevent unauthorized communication between the host computer system and one or more other devices on the trusted LAN. The second memory space may be configured to enable storage and/or operation of one or more applications and/or processes associated with a sandboxed computing environment. The host computer system may include a sandbox firewall that enforces a separation of the first and second memory spaces.

Abstract: Methods and systems are disclosed for a sandbox based internet isolation in an untrusted network. A host computer system may include a host-based firewall, an operating system, a first memory space, and a second memory space. The host-based firewall may be configured to prevent unauthorized communication between the trusted host computer system and one or more other devices on an untrusted LAN and/or the Internet. The second memory space may be configured to enable storage and/or operation of one or more applications and/or processes associated with a sandboxed computing environment. The host computer system may include a sandbox firewall that enforces separation of the first and second memory spaces.

Abstract: Methods and systems are disclosed for sandbox based internet isolation system in a trusted network. A networked computer system may include a trusted local area network (LAN) and at least one host computer system connected to the trusted LAN. The host computer system may include a host-based firewall, an operating system, a first memory space, and a second memory space. The host-based firewall may be configured to prevent unauthorized communication between the host computer system and one or more other devices on the trusted LAN. The second memory space may be configured to enable storage and/or operation of one or more applications and/or processes associated with a sandboxed computing environment. The host computer system may include a sandbox firewall that enforces a separation of the first and second memory spaces.

Abstract: Methods and systems are disclosed for a sandbox based internet isolation in an untrusted network. A host computer system may include a host-based firewall, an operating system, a first memory space, and a second memory space. The host-based firewall may be configured to prevent unauthorized communication between the trusted host computer system and one or more other devices on an untrusted LAN and/or the Internet. The second memory space may be configured to enable storage and/or operation of one or more applications and/or processes associated with a sandboxed computing environment. The host computer system may include a sandbox firewall that enforces separation of the first and second memory spaces.

Abstract: Presented herein are techniques for resolving VxAN (VSANs and VLANs) networking connectivity, prior to server or domain migration. When UCS domains receive a workload or service profile from a UCS Central Controller, required VLANs/VSANs are checked for deployment for that UCS domain in Fabric Interconnects, and once VLANs/VSANs are successfully confirmed, the workload is deployed into one of the compute servers in that domain.

Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

Abstract: Providing concurrent access to a set of shared resources is disclosed. An attempt is made, at the time it becomes necessary to use each resource required to perform an operation or set of operations, to lock the resource. For each attempt to lock a required resource, information associated with the attempt to lock the resource is stored. In the event a lock cannot be obtained with respect to a required resource, a renewed attempt to perform the operation or set of operations is initiated. At the outset of the renewed attempt, an attempt is made to lock all of the required resources that were locked or attempted to be lock during the previous attempt to perform the operation or set of operations.

Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

Abstract: Providing concurrent access to a set of shared resources is disclosed. An attempt is made, at the time it becomes necessary to use each resource required to perform an operation or set of operations, to lock the resource. For each attempt to lock a required resource, information associated with the attempt to lock the resource is stored. In the event a lock cannot be obtained with respect to a required resource, a renewed attempt to perform the operation or set of operations is initiated. At the outset of the renewed attempt, an attempt is made to lock all of the required resources that were locked or attempted to be lock during the previous attempt to perform the operation or set of operations.

Abstract: Disclosed are compounds of the formula: wherein R13 represents an imidazole ring; R14 represents a carbamate, urea, amide or sulfonamide group; R8 represents H when the alkyl chain between the amide group and the R13 imidazole group is substituted, or R8 represents a substituent such as arylalkyl, heteroarylalkyl or cycloalkyl; and the remaining substituents are as defined herein. Also disclosed are compounds wherein R8 is H, and the alkyl chain between the amide group and the R13 imidazole group is unsubstituted. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.

Abstract: Novel phenyl-substituted tricyclic compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.

Abstract: Disclosed are compounds of the formula: 1

Abstract: Novel phenyl-substituted tricyclic compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.

Abstract: Novel phenyl-substituted tricyclic compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel halo-N-substituted urea compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.

Abstract: Compounds of Formula I: ##STR1## wherein: X.sup.1 is hydrogen, halogen, CF.sub.3, nitro, NH.sub.2 or lower alkyl;each X.sup.2 is independently selected from the group consisting of hydrogen, halogen, lower alkoxy and lower alkyl;n is 1 or 2;Y is selected from the group consisting of S(O).sub.p, O, and NR.sup.5, wherein p is 0, 1 or 2, and R.sup.5 is hydrogen, alkyl, aryl, cycloalkyl, loweralkoxycarbonyl, aminocarbonyl or acyl;R.sup.1 and R.sup.2, which may be the same or different, are selected from the group consisting of hydrogen and lower alkyl groups, or taken together can form an oxygen atom when Y is NR.sup.5 ;A . . . is C=, CH-- or N--;R is --CZ--Y.sup.1 --Y.sup.2 --R.sup.3, wherein:Z is O, =CH--CN, or =N--CN;one of Y.sup.1 and Y.sup.2 is a bond, --CO--, O, S, or --NR.sup.4 --, and the other is (CH.sub.2).sub.m, where m is 0 or an integer of 1 to 4, and R.sup.4 is H or alkyl, with the proviso that when Z is O and m is 0 then Y.sup.1 or Y.sup.2 is selected from --CO--, O, S, or --NR.sup.4 ;R.sup.

Abstract: Compounds useful as antihypertensive agents and useful as antiviral agents against DNA-containing viruses, such as herpes group viruses, are disclosed. The compounds are represented by Formula 1.0: ##STR1## and their pharmaceutically acceptable salts and solvates. Pharmaceutical compositions containing compounds represented by Formula 1.0 are disclosed. Methods of treating a viral infection using compounds represented by Formula 1.0 are disclosed. Also disclosed are methods of treating hypertension using compounds of Formula 1.0 wherein R is selected from the group consisting of H, halogen and --C(O)OR.sup.6 ; and R.sup.1 is selected from the group consisting of --OR.sup.14, --O(CH.sub.2).sub.a C(H).sub.3-i Z.sub.i and --O(CH.sub.2).sub.h N(R.sup.15).sub.2.

Abstract: Compounds useful as antihypertensive agents and useful as antiviral agents against DNA-containing viruses, such as herpes group viruses, are disclosed. The compounds are represented by Formula 1.0: ##STR1## and their pharmaceutically acceptable salts and solvates. Pharmaceutical compositions containing compounds represented by Formula 1.0 are disclosed. Methods of treating a viral infection using compounds represented by Formula 1.0 are disclosed.Also disclosed are methods of treating hypertension using compounds of Formula 1.0 wherein R is selected from the group consisting of H, halogen and --C(O)OR.sup.6 ; and R.sup.1 is selected from the group consisting of --OR.sup.14, --O(CH.sub.2).sub.a C(H).sub.3-i Z.sub.i and --O(CH.sub.2).sub.h N(R.sup.15).sub.2.